Скачать с ютуб EPOS2020/EUFOREA Expert Consensus Defines Disease States and Therapeutic Goals in CRSwNP в хорошем качестве

EPOS2020/EUFOREA Expert Consensus Defines Disease States and Therapeutic Goals in CRSwNP

Severe chronic rhinosinusitis with nasal polyps or CRSwNP is a debilitating disease that significantly impacts a patient's quality of life. It is present in about 1-2% of the European population and it can be incredibly debilitating. As our understanding of the condition evolves and new treatment options become available definitions related to #CRSwNP must be constantly reviewed. With this in mind, a consensus meeting was held in June 2023 which brought together the expert panel members of EPOS2020 and EUFOREA. It sought to redefine several crucial definitions related to CRSwNP including control, remission, cure, remodelling, disease progression and modification. #openaccess Read the paper in Rhinology here: https://pubmed.ncbi.nlm.nih.gov/38217... In this show, we will discuss the work undertaken by EUFOREA and EPOS expert members to improve definitions, communication and treatment outcomes. Joining us is Prof. Dame Valerie J Lund DBE, Professor Emeritus of Rhinology at the Ear Institute, University College London. She is also an Honorary Consultant ENT Surgeon at the Royal National Throat Nose and Ear Hospital at University College Hospital in London, and Prof. Amber Luong, Professor and Surgeon-Scientist in the Dept of Otorhinolaryngology and Institute of Molecular Medicine in Houston, Texas, United States. 🗣 Interview with Prof. Dame Valerie J Lund 2:05 Tell us more about the meeting. What was its aim 5:07 How do new definitions help patients and physicians? What does this mean? 5:45 You brought together a wide range of specialities - ENT, Pulmonology, Allergology and Immunology - was that useful? 6:34 What is the value of defining remission and cure in CRSwNP? 7:37 Where does CRSwNP care to go from here? Are we all looking for a cure in the future? 🗣 Interview with Prof. Amber Luong 10:02 How and why have treatment goals in CRSwNP changed over the recent years? 12:28 Why was this consensus on novel treatment targets in CRSwNP needed? 13:39 Can you explain the difference in control, remission and cure in CRSwNP? 15:55 What difference do initiatives like this mean for the patient and future care? -------------------------------------------------------------------------------------------------------------------------- 📽 Subscribe to our YouTube Channel for our latest videos on Allergies and Airway Diseases http://bit.ly/3eMvc3E -------------------------------------------------------------------------------------------------------------------------- 📧 Get in touch with the EUFOREA team for any questions http://bit.ly/2OtlIQp -------------------------------------------------------------------------------------------------------------------------- 📌 EUFOREA is an international non-profit organisation aiming to implement optimal patient care for allergies and airway diseases (asthma, chronic rhinosinusitis, rhinitis) and comorbidities through education, research and advocacy. #euforea 📍Follow us on social media Twitter: http://bit.ly/38wrrM7 LinkedIn: http://bit.ly/2OqtWsf Instagram: http://bit.ly/3TGB5jM ​Facebook: http://bit.ly/3cnNyFF